Prime Medicine, Inc. (PRME) vs Solid Biosciences Inc. (SLDB)
A side-by-side comparison of Prime Medicine, Inc. and Solid Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PRME
Prime Medicine, Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SLDB
Solid Biosciences Inc.
$6.92HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PRME vs SLDB
growth of $100 · dividends reinvested · last 4yPRME -79.1% (-32.4%/yr)SLDB +5.2% (+1.3%/yr)SLDB compounded faster over this window
Log scale — wide-divergence pair
PRME SLDB
PRME vs SLDB: by the numbers
- •SLDB is the larger company ($681M vs $632M market cap).
- •Both run net losses; SLDB's is the smaller (0.00% vs -4613.11% net margin).
Metrics side by side
Valuation
| Metric | PRME | SLDB |
|---|---|---|
| P/S ratio | 155.21 | N/A |
| P/B ratio | 15.88 | 1.82 |
Profitability
| Metric | PRME | SLDB |
|---|---|---|
| Gross margin | -58.05% | 0.00% |
| Operating margin | -4498.06% | 0.00% |
| Net margin | -4613.11% | 0.00% |
| ROE | -471.98% | -55.36% |
| ROIC | -90.42% | -54.12% |
Growth (annualized)
| Metric | PRME | SLDB |
|---|---|---|
| Revenue CAGR (5Y) | -2.32% | N/A |
| Total return CAGR (5Y) | N/A | -27.50% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.